Plasma Catestatin Levels in Patients with Congestive Heart Failure

Liu Lin,Ding Wenhui,Zhao Feng,Chu Songyun,Han Xiaoning,Pang Yongzheng,Tang Chaoshu
DOI: https://doi.org/10.3969/j.issn.1008-9810.2009.04.052
2009-01-01
Abstract:Objective Catestatin is a newly discovered endogenous neuropeptide with potent catecholamine release-inhibitory activity.The purpose of the present study was to evaluate the possible pathophysiologic role of catestatin through investigation of plasma catestatin levels in patients with congestive heart failure(CHF).Methods Plasma catestatin was measured with enzyme-linked immunosorbent assay and norepinephine was measured with high performance liquid chromatography in 45 patients with CHF and 30 controls.Results Plasma catestatin(0.88±0.30 vs 0.41±0.14 ng/ml) and norepinephrine(421.9±61.4 vs 210.2±55.4 pg/ml) levels were significantly higher in patients with CHF than those in controls(P<0.01).Both neuroendocrine factors levels decreased after treatment,but still remained significantly higher than those in controls(P<0.01).However,in CHF patients after treatment,the catestatin/norepinephrine ratio was significantly increased(2.39±0.70 vs 1.95±0.64,P<0.01).Plasma catestatin levels were similar among patients with different NYHA classes,as well as between patients with normal and reduced ejection fraction.Plasma catestatin level was correlated positively with NTproBNP level(r=0.38,P<0.05),while no correlation was found between catestatin and left ventricular ejection fraction,hsCRP or cTNI.The area under ROC curve of catestatin in CHF for diagnosis was 0.94.Conclusion Plasma catestatin levels in patients with CHF were significantly elevated and positively correlated with NTproBNP.Catestatin might be used as a new biomarker in CHF.
What problem does this paper attempt to address?